Milestone Pharmaceuticals
MIST
80 hedge funds and large institutions have $70.7M invested in Milestone Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 9 closing their positions.
222% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 9
133% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 9
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
31% more funds holding
Funds holding: 61 → 80 (+19)
4% more capital invested
Capital invested by funds: $68.3M → $70.7M (+$2.46M)
0.92% more ownership
Funds ownership: 40.17% → 41.09% (+0.92%)
73% less call options, than puts
Call options by funds: $667K | Put options by funds: $2.47M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$2.65M |
| 2 |
Two Sigma Investments
New York
|
+$1.83M |
| 3 |
Jane Street
New York
|
+$1.47M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.43M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.97M |
| 2 |
O
OrbiMed
New York
|
-$6.44M |
| 3 |
Morgan Stanley
New York
|
-$4.71M |
| 4 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
-$2.86M |
| 5 |
PBM
Propel Bio Management
Los Angeles,
California
|
-$2.17M |
MIST Hedge Fund Activity: Q4 2025 in Review
80 of the 8,275 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q4 2025, worth a combined $70.7M — up 3.6% from $68.3M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new MIST positions and 9 closed out — a net gain of 20 holders — while 21 added to existing stakes and 9 trimmed.
The largest buyer was Marshall Wace, adding an estimated $2.65M. The largest seller was Adage Capital Partners, cutting an estimated $8.97M.
- 80 institutional investors held Milestone Pharmaceuticals (MIST) as of Q4 2025, up from 61 in Q3 2025.
- Funds reported $70.7M of Milestone Pharmaceuticals stock for Q4 2025, up 3.6% quarter-over-quarter.
- 29 funds opened new Milestone Pharmaceuticals positions in Q4 2025 and 9 closed out, a net change of +20 holders.
- The largest Milestone Pharmaceuticals buyer in Q4 2025 was Marshall Wace, an estimated $2.65M added.
- The largest Milestone Pharmaceuticals seller in Q4 2025 was Adage Capital Partners, an estimated $8.97M sold.
Based on aggregated 13F filings for Q4 2025.